Marina Bue - MolMed S Insider

MolMed S p A -- Germany Stock  

EUR 0.41  0.01  2.38%

General Manager of Business Development and Administration, Executive Director

Dr. Marina Del Bue serves as General Manager of Business Development and Administration Executive Director of Molecular Medicine S.p.A. since January 31 2011. She was General Manager since November 2000 and was in the Company Board since November 6 2007. She has over 25 years of experience in the economic management of research and development within the pharmaceutical industry. From 1981 to 1986 she conducted research for the biotechnology division of Eni Ricerche. She joined Gruppo Menarini in 1990 and gained experience as Controller of the Research and Development Division until 2000. She is Member of the Management Committee of the Cure Committee of the Healthcare Council of EuropaBio a European bio industry organization as well as Vice Chairman of Assobiotec an Italian organization for the development of biotechnology. She gained a BS in Biological Sciences from the Universita degli Studi di Roma Sapienza and obtained a Masters of Business Administration from Universita Commerciale Luigi Bocconi.
Age: 56  Director Since 2011      

Management Efficiency

The company has return on total asset (ROA) of (18.1) % which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (61.21) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Entity Summary

MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. and employs 23 people.

Did you try this?

Run Portfolio File Import Now

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
Hide  View All  NextLaunch Portfolio File Import
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add MolMed S p A to your portfolio

Top Management

MolMed S p Leadership Team
Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance

MolMed S Performance Indicators
Return On Equity(61.21) %
Return On Asset(18.1) %
Current Valuation195.6 M
Price to Earning(13.82) times
Price to Book11.53 times
Price to Sales9.28 times
Revenue22.42 M
Gross Profit1000 K
EBITDA(10.6 M)
Net Income(12.02 M)